DUBLIN--(BUSINESS WIRE)--The "mTORC-1 Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. mTORC-1 Inhibitor - Pipeline Insight, 2019 report offers ...
(HealthDay News) — The mammalian target of rapamycin complex (mTORC) pathway seems to be involved in antiphospholipid syndrome-associated vascular lesions, according to a study published in the July ...
A new study published in the New England Journal of Medicine suggests that the mammalian target of rapamycin complex (mTORC) affects vasculopathy in patients with antiphospholipid syndrome (APS).
The mammalian target of rapamycin complex (mTORC) pathway is involved in the vascular lesions that occur in patients with antiphospholipid syndrome, according to a new study. Sirolimus, an mTOR ...
Small cell carcinoma of the head and neck: Incidence and survival trends based on the Surveillance and Epidemiologic and End Results (SEER) analysis. This is an ASCO Meeting Abstract from the 2017 ...
To the Editor: Canaud et al. (July 24 issue) 1 describe the activation of the mammalian target of rapamycin complex (mTORC) through the phosphatidyl-inositol 3-kinase (PI3K)–AKT pathway in patients ...
In the April 26 Science Signaling, researchers led by Ted Abel at the University of Pennsylvania, Philadelphia, pinpointed a complex, mTORC. This kinase complex activates protein translation and is ...
A new study published in the New England Journal of Medicine suggests that the mammalian target of rapamycin complex (mTORC) affects vasculopathy in patients with antiphospholipid syndrome (APS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results